Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of LJPC-501 (Angiotensin II acetate) in Catecholamine-Resistant Hypotension
2015-002448-15Phase 3Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Catecholamine-resistant hypotension and hypotension comparing LJPC-501 (angiotensin II acetate) infusion with Placebo infusion (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2016; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Catecholamine-resistant hypotensionhypotension
Beyond the preview
Go deeper on 2015-002448-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002448-15.